The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ABHD3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ABHD3 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADM mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACADM mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C1 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C2 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANGPTL4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ANGPTL4 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of AQP3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AQP3 mRNA
[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein] ciglitazone results in increased expression of BAX protein BAX mRNA affects the susceptibility to ciglitazone
[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein]
[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein]; GAST protein inhibits the reaction [ciglitazone results in increased expression of CASP3 mRNA]
benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]
[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein]
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL20 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL20 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL15 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL15 mRNA
ciglitazone results in decreased expression of CCND1 ciglitazone results in decreased expression of CCND1 protein ciglitazone results in increased expression of CCND1 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CDH1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CDH1 mRNA; ciglitazone results in increased expression of and results in increased activity of CDH1 protein ciglitazone results in decreased expression of CDH1 mRNA
ciglitazone results in decreased expression of CDK1 protein CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein]
ciglitazone results in decreased expression of CDK4 protein CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein] ciglitazone results in decreased expression of CDK4 mRNA
ciglitazone inhibits the reaction [CREBBP protein binds to EGFR promoter]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein] CREBBP affects the susceptibility to ciglitazone
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYP1A2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CYP1A2 mRNA
ciglitazone promotes the reaction [Niflumic Acid results in increased expression of DDIT3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; DDIT3 results in increased susceptibility to [Niflumic Acid co-treated with ciglitazone]; Niflumic Acid promotes the reaction [ciglitazone results in increased expression of DDIT3 protein]
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of DOK4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of DOK4 mRNA
ciglitazone inhibits the reaction [CREBBP protein binds to EGFR promoter]; ciglitazone inhibits the reaction [NCOA1 protein binds to EGFR promoter]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]
ciglitazone results in increased phosphorylation of EIF2A protein ciglitazone promotes the reaction [Niflumic Acid results in increased phosphorylation of EIF2A protein]; Niflumic Acid promotes the reaction [ciglitazone results in increased phosphorylation of EIF2A protein]
ciglitazone promotes the reaction [Niflumic Acid results in increased phosphorylation of EIF2AK3 protein]; Niflumic Acid promotes the reaction [ciglitazone results in increased phosphorylation of EIF2AK3 protein]
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ELF5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ELF5 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of FABP1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FABP1 mRNA
[beta-hydroxy simvastatin acid co-treated with ciglitazone] results in increased expression of FADS1 mRNA ciglitazone results in increased expression of FADS1 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of FAM13A mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FAM13A mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of GALNT2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GALNT2 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of GPX3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GPX3 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of HADHA mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HADHA mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMGCS2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMGCS2 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMOX1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMOX1 mRNA
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone results in decreased secretion of IFNG protein]; ciglitazone inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; ciglitazone inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA]; ciglitazone inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; T 0070907 inhibits the reaction [ciglitazone results in decreased secretion of IFNG protein]
ciglitazone inhibits the reaction [Thioglycolates results in increased secretion of IL1B protein] ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein] ciglitazone promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; Dexamethasone inhibits the reaction [ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]]
ciglitazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]]
ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Mifepristone inhibits the reaction [ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]
ciglitazone results in increased expression of JUN mRNA [Bucladesine co-treated with ciglitazone] results in increased expression of and results in increased phosphorylation of JUN protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of JUN mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of JUN mRNA] ciglitazone results in increased expression of JUN mRNA; ciglitazone results in increased expression of JUN protein
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of LIPC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LIPC mRNA
ciglitazone results in decreased phosphorylation of MAPK1 protein ciglitazone results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK1 protein]; Glutathione inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK1 protein]
ciglitazone results in decreased phosphorylation of MAPK3 protein ciglitazone results in decreased expression of MAPK3 protein CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein] ciglitazone results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK3 protein]; Glutathione inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK3 protein]
CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein]
ciglitazone inhibits the reaction [NCOA1 protein binds to EGFR promoter]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein] NCOA1 affects the susceptibility to ciglitazone
ciglitazone inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; ciglitazone inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of OAS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OAS1 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of OPTN mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OPTN mRNA
benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]; ciglitazone results in increased cleavage of and results in increased activity of PARP1 protein; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PCK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PCK1 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PDZK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PDZK1 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PIM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PIM1 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLIN2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PLIN2 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of POR mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of POR mRNA
ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [ciglitazone results in increased expression of PPARA mRNA]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PPARA mRNA] ciglitazone results in decreased expression of PPARA mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ABHD3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACAA2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADM mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADVL mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACSM3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANG mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANGPTL4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of APOL1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of APOM mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AQP3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ARHGEF2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ATF7IP2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BCL6 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BDH1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BHMT mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BLVRB mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CAT mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL14 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL15 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL20 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CDH1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CIDEC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of COBLL1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of COPA mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CSTB mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CTSC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYB5R3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYP1A2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DKK1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DLC1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DOK4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of EEIG1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of EFNA1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ELF5 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FABP1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FAM13A mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FLNB mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GALNT2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GCN1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GK mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GK3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GPX3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GRAMD2B mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HADHA mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HAMP mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMGCS2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMOX1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HPN mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ITIH3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LIPC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LMCD1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LOX mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LPCAT1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAGED4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAGED4B mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAP4K3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAPK14 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MKI67 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MTMR4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NDRG2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NR1H3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NREP mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of OAS1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of OPTN mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PALM2AKAP2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PCK1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PDZK1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PHLPP1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PIM1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLA2G2A mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLAC8 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLCXD1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLIN2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLSCR4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PMM1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of POR mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PRKCD mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PSD4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RETSAT mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RNASE4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RNF128 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RPS6KC1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of S100P mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEC23A mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEMA3G mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEPTIN10 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SERPINE1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC30A10 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC50A1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SNRK mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SORL1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SOWAHC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of STBD1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SUN2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TCAF1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TIMP3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TMEM53 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TNS1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TRAF3IP2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of UGT1A6 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of UGT1A9 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of VEGFA mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of VNN1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ZNF185 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ABHD3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACAA1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACADM mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACSL1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ANGPTL4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AQP3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL14 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL15 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL20 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CDH1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CEBPD mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CHMP5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CITED2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CYP1A2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of DOK4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ELF5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of EPAS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FABP1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FAM13A mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FOXO1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GALNT2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GPX3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HADHA mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HCAR3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMGCS2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMOX1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of IL1R1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of IL6ST mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ITGB5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of JAG1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LGALS3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LIPC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LPCAT3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of MPC1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of MPZL2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of NPC1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OAS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OPTN mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OSMR mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PCK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PDZK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PHKA2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PIM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PLIN2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PNRC1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of POR mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of RBMS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of RNF10 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of S100P mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SERPINE1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SLC30A10 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SLC4A7 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SORL1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SOWAHC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SQSTM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of STBD1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of STX7 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TBC1D4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TCAF1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TGIF1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TMBIM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of VEGFA mRNA; ciglitazone binds to and results in decreased activity of PPARG protein; ciglitazone binds to and results in increased activity of PPARG protein; ciglitazone inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARG mRNA]; ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]; monobutyl phthalate inhibits the reaction [ciglitazone binds to and results in increased activity of PPARG protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [ciglitazone results in increased expression of PPARG mRNA]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PPARG mRNA]; norathyriol inhibits the reaction [ciglitazone results in increased activity of PPARG protein]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 protein]; PPARG protein promotes the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]; PPARG protein promotes the reaction [ciglitazone results in increased activity of DIO2 protein]; Quercetin inhibits the reaction [ciglitazone results in increased activity of PPARG protein] ciglitazone results in increased expression of PPARG mRNA; ciglitazone results in increased expression of PPARG protein [ciglitazone binds to and results in increased activity of PPARG protein] which results in increased transport of Glucose; ciglitazone binds to and results in increased activity of PPARG protein; ciglitazone inhibits the reaction [Glycerol results in decreased expression of PPARG protein] [ciglitazone co-treated with Bucladesine] affects the expression of PPARG mRNA; [ciglitazone co-treated with Bucladesine] results in increased expression of PPARG protein; ciglitazone binds to and results in increased activity of PPARG protein; ciglitazone inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; ciglitazone inhibits the reaction [PPARG protein results in increased susceptibility to Methamphetamine]; PPARG protein promotes the reaction [ciglitazone results in increased expression of PPARGC1A mRNA] ciglitazone results in increased localization of PPARG protein PPARG protein mutant form results in decreased susceptibility to ciglitazone ciglitazone affects the localization of PPARG protein
ciglitazone results in increased expression of PPARGC1A mRNA PPARG protein promotes the reaction [ciglitazone results in increased expression of PPARGC1A mRNA]
2-chloro-5-nitrobenzanilide inhibits the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [ciglitazone results in increased expression of PTGS2 protein]; [Cisplatin co-treated with ciglitazone] results in decreased expression of PTGS2; ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]; ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]; ciglitazone results in increased expression of and results in increased activity of PTGS2 protein; Dexamethasone inhibits the reaction [ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]]; Dexamethasone inhibits the reaction [ciglitazone results in increased expression of and results in increased activity of PTGS2 protein]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PTGS2 protein]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 protein] ciglitazone affects the expression of PTGS2 protein ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] ciglitazone promotes the reaction [[PAR-1-activating peptide results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; ciglitazone promotes the reaction [PAR-1-activating peptide results in increased expression of PTGS2 protein] ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]; ciglitazone results in increased expression of PTGS2 mRNA; ciglitazone results in increased expression of PTGS2 protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]; ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]; NR2F1 protein promotes the reaction [[SR 11237 co-treated with ciglitazone] results in increased expression of RARB protein]; PPARG protein promotes the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SERPINE1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SERPINE1 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC30A10 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SLC30A10 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SORL1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SORL1 mRNA
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SOWAHC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SOWAHC mRNA
[Bucladesine co-treated with ciglitazone] results in increased expression of STAR mRNA; [Bucladesine co-treated with ciglitazone] results in increased phosphorylation of STAR protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR protein]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR protein]
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of STBD1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of STBD1 mRNA
[ciglitazone binds to PPARG protein] which results in increased expression of TBC1D4 mRNA ciglitazone results in increased phosphorylation of TBC1D4 protein
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of TCAF1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TCAF1 mRNA
ciglitazone inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; ciglitazone inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]
[[Cisplatin co-treated with ciglitazone] results in decreased expression of VEGFA] which results in decreased abundance of Dinoprostone; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of VEGFA mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of VEGFA mRNA; [Cisplatin co-treated with ciglitazone] results in decreased expression of VEGFA ciglitazone results in increased expression of VEGFA mRNA